This cluster groups 2 independently calculated changes: Cash & equivalents increased 24.6%; Operating cash flow increased 77.2%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTTenaya Therapeutics, Inc.'s latest supported as-filed period reports revenue of $1.1M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 24.6%; Operating cash flow increased 77.2%.
2 evidence-backed componentsFree-cash-flow proxy changed +76.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TNYA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-389563SEC ↗4Sep 11, 2026Period Sep 10, 20260001193125-26-389561SEC ↗4Aug 17, 2026Period Aug 17, 20260001193125-26-354518SEC ↗4Aug 17, 2026Period Aug 17, 20260001193125-26-354517SEC ↗10-QAug 5, 2026Period Jun 30, 20260001193125-26-335140SEC ↗8-KAug 5, 2026Period Aug 5, 20260001193125-26-335098SEC ↗4Jul 14, 2026Period Jul 13, 20260001193125-26-303681SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 10, 2026Filed Sep 11, 2026 | Ali FarazChief Executive Officer | Grant Or AwardDirect | 122,000 | $0 | $0 | Form 4 ↗ |
| Sep 10, 2026Filed Sep 11, 2026 | Ali FarazChief Executive Officer | Grant Or AwardDirect | 732,500 | $0 | $0 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 17, 2026 | Ali FarazChief Executive Officer | Open Market SaleDirect | 5,837 | $1 | $4,143 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 17, 2026 | Ali FarazChief Executive Officer | Open Market SaleDirect | 3,969 | $1 | $2,817 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 17, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed +77.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +50.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed -83.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Working capital / assets changed +1986 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Shares outstanding changed +37.6% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes.
Stock-based compensation changed -53.2% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-294879| Ali FarazChief Executive Officer |
| Open Market SaleDirect |
| 5,020 |
| $1 |
| $3,563 |
| Form 4 ↗ |
| Aug 17, 2026Filed Aug 17, 2026 | Ali FarazChief Executive Officer | Open Market SaleDirect | 7,406 | $1 | $5,256 | Form 4 ↗ |